Payment overview · 2025
General Payments
$905.20
25 reported records · 13 companies
Healthcare provider profile · identity verified
Vikas Merchia, M.D.
Allopathic & Osteopathic Physicians|Obstetrics & Gynecology|Urogynecology and Reconstructive Pelvic Surgery · BROCKTON, MA · NPI 1811966948
Verified facts
What the public records show
CMS Open Payments records show Vikas Merchia, M.D. received $905.20 in general payments during 2025 across 25 reported records.
DENTSPLY IH AB accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| DENTSPLY IH AB | Unresolved — no canonical attribution shown | $169.34 | 18.7% | 5 | 2025 |
| Minerva Surgical, Inc | Unresolved — no canonical attribution shown | $166.02 | 18.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $92.50 | 10.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$90.53 | 10.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $74.72 | 8.2% | 2 | 2025 |
| CooperSurgical, Inc. | Unresolved — no canonical attribution shown | $62.38 | 6.9% | 2 | 2025 |
| 180 Medical, Inc. | Unresolved — no canonical attribution shown | $56.99 | 6.3% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $56.54 | 6.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $49.41 | 5.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.21 | 3.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $23.78 | 2.6% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $19.28 | 2.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.50 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $905.20 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LOFRIC Normalized: lofric |
Device | DENTSPLY IH AB | $169.34 | 5 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $76.61 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $63.41 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $56.54 | 2 | 2025 |
Source payment records
|
|||||
| Advantage System Normalized: advantage system |
Device | Boston Scientific Corporation | $56.08 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $49.41 | 2 | 2025 |
Source payment records
|
|||||
| Endosee Normalized: endosee |
Device | CooperSurgical, Inc. | $43.54 | 1 | 2025 |
Source payment records
|
|||||
| GENTLECATH GLIDE Normalized: gentlecath glide |
Device | 180 Medical, Inc. | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.09 | 1 | 2025 |
Source payment records
|
|||||
| LO LOESTRIN FE Normalized: lo loestrin fe |
Drug | ABBVIE INC. | $28.21 | 1 | 2025 |
Source payment records
|
|||||
| GENTLECATH Normalized: gentlecath |
Device | 180 Medical, Inc. | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| Paragard T 380A Normalized: paragard t 380a |
Drug | CooperSurgical, Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| Solyx SIS System Normalized: solyx sis system |
Device | Boston Scientific Corporation | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| V-LOC 180 Normalized: v loc 180 |
Device | Medtronic, Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Estradiol | Estradiol | 117 | 72 |
| Estring | Estradiol | 78 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 28 |
| Estradiol (Once Weekly) | Estradiol | 39 | 11 |
| Femring | Estradiol Acetate | 25 | suppressed |
| Naproxen | Naproxen | 23 | 23 |
| Gemtesa | Vibegron | 21 | suppressed |
| Metronidazole | Metronidazole | 20 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Premarin | Estrogens, Conjugated | 15 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 14 | suppressed |
| Misoprostol | Misoprostol | 14 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $905.20 · 25 records | DENTSPLY IH AB | ACCRUFER, Advantage System, Cologuard Collection Kit, Endosee, GEMTESA, GENTLECATH, GENTLECATH GLIDE, IBSRELA, INTERSTIM, JOURNAVX, LO LOESTRIN FE, LOFRIC, NP Thyroid 60, Paragard T 380A, Solyx SIS System, The Cologuard Plus Collection Kit, V-LOC 180 | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Sumitomo Pharma America, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error